Financials
Financial year 2025
Worth noting
- The team shrank two years in a row.
Revenue
€ 147.9 million
▲ 20% vs 2024
Profit
Growing€ 3.7 million
▲ 112% vs 2024
Debts
Low€ 56.8 million
▼ 29% vs 2024
ABLYNX from Gent, company number BE0475295446, closed financial year 2025 with a result of € 3.7 million after tax. For that financial year ABLYNX recorded revenue of € 147.9 million and equity of € 359.2 million. Compared with financial year 2024, the result moved from € -32.1 million to € 3.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
What happened at ABLYNX?
What happened at ABLYNX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Geert Deschamps stepped down as director. NBB
- Hao Zheng stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 3.7 million. Source: NBB ↗
- Hao Zheng became a director. NBB
- Geert Deschamps became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 31.9 million profit in 2021 to € 3.7 million profit in 2025.
Paid € 3 million in corporate taxes since 2021.
Best year ever: 2021, with € 31.9 million profit.
Pays suppliers within 141 days on average.
A new publication or filing at ABLYNX? We notify you, reason included.
Follow ABLYNXNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Sanofi Foreign Participations B.V. and Sanofi Développement Pharma.
Directors
According to the 2025 annual accounts
Geert Deschamps
Managing director
since 2025 · until 2028
since 2025 · until 2028
Shareholders
Sanofi Foreign Participations B.V.
Sanofi Développement Pharma
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 21
9052 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Mimecast
Hosting
AMAZON-02 - Amazon.com, Inc., US
Domain
Domain
ablynx.com
Registered
2002-01-17
Registrar
CSC Corporate Domains, Inc.
Expires
2027-01-17
Website info
Features
Security
Details
- Company number
- 0475.295.446
- VAT number
- BE 0475.295.446
- Registered office
- Technologiepark-Zwijnaarde 21, 9052 Gent
- Names & denominations
- ABLYNX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 July 2001
- Peppol
- Active · Active since 2 Jun 2026
- Contact
- ablynx.com
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige technische testen en toetsen
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Technische testen en analyses
+1